Drug Staves Off Graft-vs-Host Disease – MedPage Today

Some encouraging results from a trial of Maraviroc (or Selzentry) to reduce the risk of Graft vs Host Disease following allogeneic stem cell transplants, particularly with respect to liver and gut-related GvHD. Unclear to date whether benefits are limited to short-term (3-6 months) or whether they also apply in the longer-term.

Medical News: Drug Staves Off Graft-vs-Host Disease – in Transplantation, Transplantation from MedPage Today.

About these ads

What do you think?

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s